Frontiers in Immunology (Oct 2024)

Prognostic value of T regulatory cells and immune checkpoints expression in tumor-draining lymph nodes for oral squamous cell carcinoma

  • Krzysztof Piersiala,
  • Krzysztof Piersiala,
  • Eric Hjalmarsson,
  • Vilma Lagebro,
  • Pedro Farrajota Neves da Silva,
  • Rusana Bark,
  • Rusana Bark,
  • Alexandra Elliot,
  • Alexandra Elliot,
  • Linda Marklund,
  • Linda Marklund,
  • Linda Marklund,
  • Gregori Margolin,
  • Gregori Margolin,
  • Susanna Kumlien Georén,
  • Susanna Kumlien Georén,
  • Lars-Olaf Cardell,
  • Lars-Olaf Cardell

DOI
https://doi.org/10.3389/fimmu.2024.1455426
Journal volume & issue
Vol. 15

Abstract

Read online

Despite the employment of extensive therapeutic strategies, OSCC recurrence and mortality rates persist at high levels. This underscores the shortcomings of current prognostic models and the urgency for refined biomarkers. This study explores the prognostic significance of tumor-draining lymph nodes (TDLNs) in OSCC, with a special focus on the quantification of T regulatory cells (Tregs) and the expression of immune checkpoints on T cells.MethodsForty-nine OSCC patients were enrolled. One TDLN per patient was analysed using flow cytometry to profile immune-checkpoint expression (PD-1, CTLA-4, TIGIT, TIM-3, LAG-3) and other markers such as CD69, CXCR5 on CD4+, CD8+, and Tregs. Disease-free survival (DFS) and overall survival (OS) were assessed.ResultsAccording to multivariate analysis, elevated levels of FoxP3+CD4+ and TIGIT+CD8+ cells in TDLNs correlated with significantly worse DFS, while high CXCR5+CD4+ levels were associated with better DFS. Notably, the expression of immune checkpoints on T cells within TDLNs showed significant associations with recurrence status. Patients experiencing recurrence exhibited heightened levels of T regulatory cells, CD4+PD-1+ and CD4+CTLA-4+, cells in TDLNs. Survival multivariate analyses revealed that T status emerged as an independent predictor of OS.ConclusionThe findings highlight the critical role of TDLNs in the immune microenvironment of OSCC and establish immune checkpoint expression on T cells as promising prognostic biomarkers. These insights upgrade the prognostic framework for OSCC and pave the way for individualized therapeutic strategies. The prognostic significance of TDLNs and a high expression of immune checkpoint inhibitors is a compelling argument for the adoption of neoadjuvant immunotherapy.

Keywords